CSL shares have seen a significant downturn due to recent challenges, yet analysts see potential for recovery, with a projected rebound to $275, driven by its strong foundation and global healthcare ...

Abstract: Existing technologies for patients with respiratory insufficiency have focused on providing reliable assistance in their breathing. However, the need for assistance in other everyday ...

Australia's CSL, which earlier this year paused plans to put its CSL Seqirus vaccine division up for sale, has opened the doors to a new $1 billion cell-based influenza vaccine and antivenom ...

Three years after introducing Hemgenix, the first gene therapy for hemophilia B, CSL Behring has released long-term data proving the treatment’s benefits remain durable after five years. The five-year ...

EXO is officially making a comeback in early 2026, marking their first group album in years—though it won’t be a full reunion. The group was on hiatus for a long period filled with military ...

A leading investment expert says ASX investors have a rare chance to buy CSL shares at a discount. CSL shares remain down 35.2% over the past year, impacted by concerns over vaccine sales and ...